Skip to main content
. 2017 Oct;9(Suppl 13):S1364–S1372. doi: 10.21037/jtd.2017.09.59

Figure 1.

Figure 1

The clinical case of a 48-year-old man, diagnosed with a stage IV lung adenocarcinoma KRAS mutant. The patient was included in the SLIPP study. The allelic fraction of the KRAS mutant allele was significantly increased at the time of progression to first line chemotherapy. cfDNA, cell-free DNA; SLIPP, the Spanish Lung Liquid versus Invasive Biopsy Program.